2-bromo-1-(2,6-dimethylphenyl)ethanone | 2633-42-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-bromo-1-(2,6-dimethylphenyl)ethanone
• 英文别名: 2-bromo-1-(2,6-dimethylphenyl)ethan-1-one；2-bromo-2',6'-dimethylacetophenone；2,6-dimethyl-α-bromoacetophenone
• CAS: 2633-42-3
• 化学式: C₁₀H₁₁BrO
• 分子量: 227.101
• InChiKey: YSICJHNHYWMNBM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-bromo-1-(2,6-dimethylphenyl)ethanone 在 N-溴代丁二酰亚胺(NBS) 、 亚硝酸特丁酯 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 6.0h， 生成 5-bromo-4-(2,6-dimethylphenyl)thiazole
  参考文献：
  名称：

  [EN] 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY
  [FR] HÉTÉROARYLAMINOSULFONAMIDES À 5 CHAÎNONS POUR LE TRAITEMENT D'ÉTATS À MÉDIATION PAR UNE ACTIVITÉ CFTR DÉFICIENTE

  摘要：

  这项发明涉及杂环芳基化合物，其药用盐以及药物制剂。本文还描述了这些化合物的组成以及在治疗由CFTR活性不足介导的疾病和病况的方法中的使用，特别是囊性纤维化。

  公开号：

  WO2021097057A1
• 作为产物：
  描述：

  2,6-二甲基溴苯 在 正丁基锂 、 pyridinium chlorochromate 、 copper(I) bromide 作用下， 以 四氢呋喃 、 正己烷 、 二氯甲烷 、 氯仿 、 乙酸乙酯 为溶剂， 反应 12.5h， 生成 2-bromo-1-(2,6-dimethylphenyl)ethanone
  参考文献：
  名称：

  Optimization of Inhibitors of the Tyrosine Kinase EphB4. 2. Cellular Potency Improvement and Binding Mode Validation by X-ray Crystallography

  摘要：

  Inhibition of the tyrosine kinase erythropoietin-producing human hepatocellular carcinoma receptor B4 (EphB4) is an effective strategy for the treatment of solid tumors. We have previously reported a low nanomolar ATP-competitive inhibitor of EphB4 discovered in silico by fragment-based high-throughput docking combined with explicit solvent molecular dynamics simulations. Here we present a second generation of EphB4 inhibitors that show high inhibitory potency in both enzymatic and cell-based assays while preserving the appealing selectivity profile exhibited by the parent compound. In addition, respectable levels of antiproliferative activity for these compounds have been obtained. Finally, the binding mode predicted by docking and molecular dynamics simulations is validated by solving the crystal structures of three members of this chemical class in complex with the EphA3 tyrosine kinase whose ATP-binding site is essentially identical to that of EphB4.

  DOI：

  10.1021/jm301187e

文献信息

• Alkenyl Bromides by Brominative Deoxygenation of Ketones in One or Two Steps
  作者：Ulrich Von Roman、Jakob Ruhdorfer、Rudolf Knorr

  DOI：10.1055/s-1993-25986

  日期：——

  The conversion of ketones into alkenyl bromides is accomplished in one or two steps by 2,2,2-tribromo-2,2-dihydro-1,3,2-benzodioxaphosphole or by the dibromomethyl methyl ether prepared therefrom. Investigations of the scope and limitations provide some hints for the preparative planning and improvement.

  通过使用2,2,2-三溴-2,2-二氢-1,3,2-苯并二氧磷杂环己烯或由此制备的二溴甲基甲醚，可以将酮转化为烯基溴，这一过程在一到两步内完成。对范畴和限制条件的研究为制备规划和改进提供了一些线索。
• Phenyl-and phenylalkyl-substituted ethanolamines and ethylenediamines
  申请人：——

  公开号：US20020042410A1

  公开（公告）日：2002-04-11

  Compounds of formula 1, 1 wherein: R 1 is hydrogen, hydroxy, CF 3 , NO 2 , CN, halogen, C 1 -C 8 -alkyl, or C 1 -C 8 -alkoxy; R 2 , R 3 , and R 4 independently of one another are hydrogen, C 1 -C 8 -alkyl, hydroxy, NO 2 , CN, C 1 -C 8 -alkyloxy, CF 3 , or halogen; R 5 and R 6 independently of one another are hydrogen or a group consisting of C 1 -C 8 -alkyl, C 2 -C 8 -alkenyl, C 3 -C 8 -alkynyl, C 3 -C 8 -cycloalkyl, C 3 -C 8 -cycloalkyl-C 1 -C 6 -alkylene, C 5 -C 8 -cycloalkenyl, C 5 -C 8 -cycloalkenyl-C 1 -C 6 -alkylene, C 6 -C 10 -aryl, and C 6 -C 10 -aryl-C 1 -C 6 -alkylene, each optionally substituted by a group consisting of C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, halogen, C 1 -C 6 -alkyloxy, —NH 2 , —NH(C 1 -C 4 -alkyl), —N(C 1 -C 4 -alkyl) 2 , hydroxy, ═O, —COOH, —CO—OC 1 -C 4 -alkyl, —CONH 2 , —CONH(C 1 -C 4 -alkyl), —CON(C 1 -C 4 -alkyl) 2 , and CF 3 , or R 5 and R 6 together with the nitrogen atom are a saturated or unsaturated 5-, 6-, 7-, or 8-membered heterocyclic group optionally containing one or two further heteroatoms consisting of sulfur, oxygen, and nitrogen, and optionally mono-, di-, or trisubstituted by a group consisting of C 1 -C 4 -alkyl, hydroxy, ═O, —COOH, —CO—OC 1 -C 4 -alkyl, —CONH 2 , —CONH(C 1 -C 4 -alkyl), —CON(C 1 -C 4 -alkyl) 2 , halogen, and benzyl; X is oxygen, —NH—, —N(CHO)—, —N(CO—C 1 -C 6 -alkyl), —N(C 1 -C 6 -alkyl), or —N(C 3 -C 6 -cycloalkyl-C 1 -C 4 -alkylene); and A is a group consisting of C 1 -C 6 -alkylene, C 2 -C 6 -alkenylene, and C 3 -C 6 -alkynylene, each optionally substituted by a group consisting of halogen, ═O, and hydroxy, or an optical isomer, enantiomer, tautomer, free base, or pharmacologically acceptable acid addition salt thereof; methods of making such compounds; pharmaceutical compositions thereof, and their use in treating or preventing certain diseases.

  式为1,1的化合物，其中：R1为氢，羟基，CF3，NO2，CN，卤素，C1-C8烷基或C1-C8烷氧基；R2，R3和R4各自独立地为氢，C1-C8烷基，羟基，NO2，CN，C1-C8烷氧基，CF3或卤素；R5和R6各自独立地为氢或由C1-C8烷基，C2-C8烯基，C3-C8炔基，C3-C8环烷基，C3-C8环烷基-C1-C6-烷基，C5-C8环烯基，C5-C8环烯基-C1-C6-烷基，C6-C10芳基和C6-C10芳基-C1-C6-烷基组成的基团，每个基团可以选择地被C1-C6烷基，C2-C6烯基，卤素，C1-C6烷氧基，—NH2，—NH（C1-C4烷基），—N（C1-C4烷基）2，羟基，═O，—COOH，—CO—OC1-C4-烷基，—CONH2，—CONH（C1-C4烷基），—CON（C1-C4烷基）2和CF3中的一个基团替代，或R5和R6与氮原子一起是饱和或不饱和的5、6、7或8成员杂环基团，可选择地包含硫、氧和氮的一个或两个进一步杂原子，并且可选择地被C1-C4烷基，羟基，═O，—COOH，—CO—OC1-C4-烷基，—CONH2，—CONH（C1-C4烷基），—CON（C1-C4烷基）2，卤素和苄基中的一个基团单取代、双取代或三取代；X为氧、—NH—、—N（CHO）—、—N（CO—C1-C6-烷基）、—N（C1-C6-烷基）或—N（C3-C6-环烷基-C1-C4-烷基）；A为由C1-C6烷基，C2-C6烯基和C3-C6炔基组成的基团，每个基团可以选择地被卤素、═O和羟基替代，或其光学异构体、对映异构体、互变异构体、自由碱、药理学上可接受的酸加成盐；制备这些化合物的方法；这些化合物的药物组合物及其用于治疗或预防某些疾病的用途。
• Compounds, pharmaceutical compositions, and methods for inhibiting cyclin-dependent kinases
  申请人：——

  公开号：US20030220326A1

  公开（公告）日：2003-11-27

  Pharmaceutical compositions containing effective amounts of CDK-inhibiting diaminothiazole compounds of the following formula (where R 1 and R 2 are as defined in the specification) or their salts, or prodrugs or active metabolites of such compounds or salts, are useful for treating disorders and diseases such as cancer: 1 In preferred embodiments, R 1 and R 2 are independently unsubstituted or substituted carbocyclic or heterocyclic aryl ring structures. Compounds where R 2 is ortho-substituted aryl are especially potent inhibitors of CDKs such as CDK4.

  含有以下公式中CDK抑制二氨基噻唑化合物的有效量的药物组合物（其中R1和R2如规范所定义）或其盐，或这些化合物或盐的前药或活性代谢物，可用于治疗癌症等疾病和疾病。在首选实施例中，R1和R2分别是未取代或取代的碳环或杂环芳香环结构。其中R2为邻位取代芳香族的化合物特别是CDKs如CDK4的有效抑制剂。
• Electrochemically Promoted [3 + 2] Annulation of Imidazo[1,2-<i>a</i>]pyridine with Alkynes
  作者：Meng-Qi Ping、Ming-Zhong Guo、Rui-Tao Li、Zi-Chen Wang、Cheng Ma、Li-Rong Wen、Shao-Fei Ni、Weisi Guo、Ming Li、Lin-Bao Zhang

  DOI：10.1021/acs.orglett.2c02980

  日期：2022.10.14

  The efficient electrochemically promoted [3 + 2] annulation of imidazo[1,2-a]pyridines with alkynes using traceless electrons as green reagents has been developed, leading to the synthesis of a large class of polycyclic heteroaromatics in good yields with a broad substrate scope under mild and green conditions. The scaled-up experiment, follow-up procedures, and potential biological applications show

  使用无痕电子作为绿色试剂，开发了咪唑并[1,2- a ]吡啶与炔烃的高效电化学促进[3 + 2]成环反应，从而可以在广泛的底物下以良好的产率合成一大类多环杂芳烃在温和和绿色条件下的范围。放大实验、后续程序和潜在的生物学应用表明了电化学方法的实用性和可行性。
• Structure-activity relationship studies in substituted sulfamoyl benzamidothiazoles that prolong NF-κB activation
  作者：Nikunj M. Shukla、Michael Chan、Fitzgerald S. Lao、Paul J. Chu、Masiel Belsuzarri、Shiyin Yao、Jason Nan、Fumi Sato-Kaneko、Tetsuya Saito、Tomoko Hayashi、Maripat Corr、Dennis A. Carson、Howard B. Cottam

  DOI：10.1016/j.bmc.2021.116242

  日期：2021.8